Anesthetic Effect - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anesthetic Effect - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Anesthetic Effect - Pipeline Review, H1 2015', provides an overview of the Anesthetic Effect's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anesthetic Effect and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anesthetic Effect pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anesthetic Effect Overview 9
Therapeutics Development 10
Pipeline Products for Anesthetic Effect - Overview 10
Pipeline Products for Anesthetic Effect - Comparative Analysis 11
Anesthetic Effect - Therapeutics under Development by Companies 12
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 14
Anesthetic Effect - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anesthetic Effect - Products under Development by Companies 19
Anesthetic Effect - Products under Investigation by Universities/Institutes 21
Anesthetic Effect - Companies Involved in Therapeutics Development 22
Advicenne Pharma 22
Biolab Sanus Farmaceutica Ltda. 23
Drawbridge Pharmaceuticals Pty Ltd 24
Jiangsu Hengrui Medicine Co., Ltd. 25
Juniper Pharmaceuticals, Inc. 26
Laboratoires Thea S.A. 27
Lipicard Technologies Limited 28
Merck & Co., Inc. 29
NanoMedex Pharmaceuticals, Inc. 30
Paion AG 31
Phosphagenics Limited 32
Physica Pharma 33
Proteus SA 34
Sphaera Pharma Pvt. Ltd. 35
Taiwan Liposome Company, Ltd. 36
The Medicines Company 37
Anesthetic Effect - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 47
(lidocaine + phenylephrine hydrochloride + tropicamide) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(tetracaine + oxymetazoline hydrochloride) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ABP-700 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ADV-6209 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alphaxalone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bupivacaine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
carboetomidate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gabafol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lidocaine ER - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LT-1121 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LT-1123 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
methoxycarbonyl carboetomidate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
methoxycarbonyl etomidate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
neosaxitoxin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PB-5109 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PHY-301 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
propofol - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
propofol microemulsion - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
propofol-DM - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
remimazolam - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
remimazolam - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
sugammadex sodium - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Anesthetic Effect - Recent Pipeline Updates 77
Anesthetic Effect - Dormant Projects 82
Anesthetic Effect - Discontinued Products 84
Anesthetic Effect - Product Development Milestones 85
Featured News & Press Releases 85
Apr 28, 2015: FDA Declines To Approve Merck's Bridion 85
Mar 13, 2015: Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection 85
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 85
Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 86
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 86
Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 86
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 87
Sep 15, 2014: Drawbridge Pharmaceuticals to present clinical findings of Phaxan at Anesthesiology 2014 88
Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids 89
Jun 18, 2014: Drawbridge Pharmaceuticals granted new anaesthesia patent for Phaxan in China 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Anesthetic Effect, H1 2015 10
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Anesthetic Effect - Pipeline by Advicenne Pharma, H1 2015 22
Anesthetic Effect - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 23
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2015 24
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 25
Anesthetic Effect - Pipeline by Juniper Pharmaceuticals, Inc., H1 2015 26
Anesthetic Effect - Pipeline by Laboratoires Thea S.A., H1 2015 27
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H1 2015 28
Anesthetic Effect - Pipeline by Merck & Co., Inc., H1 2015 29
Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2015 30
Anesthetic Effect - Pipeline by Paion AG, H1 2015 31
Anesthetic Effect - Pipeline by Phosphagenics Limited, H1 2015 32
Anesthetic Effect - Pipeline by Physica Pharma, H1 2015 33
Anesthetic Effect - Pipeline by Proteus SA, H1 2015 34
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 35
Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H1 2015 36
Anesthetic Effect - Pipeline by The Medicines Company, H1 2015 37
Assessment by Monotherapy Products, H1 2015 38
Assessment by Combination Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 46
Anesthetic Effect Therapeutics - Recent Pipeline Updates, H1 2015 77
Anesthetic Effect - Dormant Projects, H1 2015 82
Anesthetic Effect - Dormant Projects (Contd..1), H1 2015 83
Anesthetic Effect - Discontinued Products, H1 2015 84